Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
about
First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertensionBeta-blockers for hypertensionBeta-blockers for hypertensionBeta-blockers for hypertensionChronobiologically explored effects of TelmisartanFixed combination of losartan and hydrochlorothiazide and reduction of risk of strokeBeta-blockers for hypertension.Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study.Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review.Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists.Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle interventionTreating hypertension in the elderly.Therapeutic potential of angiotensin II receptor antagonists.Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment.Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes.The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy.Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?Clinical characterization of symptomatic microangiopathic brain lesionsEffects of antihypertensive agents on the left ventricle: clinical implications.Association between hyperuricemia and atrial fibrillation in rural China: a cross-sectional study.Sitting on the evidence: what is the proper patient position for the office measurement of blood pressure?Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy.Prevalence and characteristics of resistant hypertension at primary clinics in Korea: a nationwide cross-sectional studySaving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy.Left Ventricular Hypertrophy Phenotype in Childhood-Onset Essential Hypertension.Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.Diabetes mellitus is an independent risk factor for atrial fibrillation in a general Chinese populationRole of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.Spectrum of use for the angiotensin-receptor blocking drugs.Short-term blood pressure variability over 24 h and target organ damage in middle-aged men and women.In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.Haemochromatosis genotype and iron overload: association with hypertension and left ventricular hypertrophy.Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study.Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.Vasodilatory capacity and vascular structure in long-standing hypertension: a LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension.The past, present and future of hypertension management: a potential role for AT(1)-receptor antagonists.
P2860
Q24186647-F83A7D56-4F22-4E52-9F24-4728D85DBFAAQ24201511-0B1113B7-AFC7-4695-8E61-A202E6635430Q24202812-A9830EEE-6F40-4B15-BAD0-DCF4E39658C0Q24243099-8AF020AD-EB49-4B11-B4AE-A22F88412B71Q28174117-BD0F2E4C-49E0-434A-8F58-6DDFA1249DC3Q28219593-6A4374A7-624F-455A-AD1E-C98C256ECDF8Q30238911-89782094-4754-47BF-9BA2-630849870CEAQ31149033-9954DE12-EF82-4B26-8263-008DF929F53EQ33300205-BEABB40A-ADB8-458B-91B3-9D34659927DBQ33839744-FA314B28-4850-4B69-9A70-2A8C1546654AQ34178727-5DA851EE-30E1-4781-8DF4-08D6C19A0FF6Q34422247-9DA35775-BC06-4C79-9B8D-188E148AA500Q34481715-B9866CFE-E1A4-4753-BD7F-36A9DFF5AA48Q34553606-2102B990-494E-4078-820E-DF20D9691DA2Q34633316-2C6D31E8-688E-4401-8052-DEA60BA797CDQ34915626-BFF8654C-21D1-43D9-AC46-BF602F21B828Q34962208-EE21B099-2036-49FB-8CF9-A3225AE83829Q35154540-12821F7C-BDEF-4394-B40B-A5772FCD2FFCQ35154543-3B2BC3E2-1514-4993-ABD2-E6FDAFF35F26Q35226487-9BB2840D-C183-496E-81F7-7D83E2791ECCQ35631328-C0B5C49D-44C4-4911-97DE-5D4612AF9FF5Q36008874-336EA9F1-C317-49D6-B75E-0929B49B0555Q36222801-63BBEE1C-0AD1-4C3B-AB89-9A0D5242A2ABQ36360341-4E5705AB-D556-458B-BA32-E9D13DC001A4Q36572325-3EBABDDF-8181-4478-80BB-982891751517Q36697579-041E26B0-9DA0-41A5-8A77-CA4570D7D821Q36768148-AC0C5B3B-2BBB-47FE-9F77-99381B5C7C83Q37221268-9CCD230E-EE16-42EC-B400-7533B79F3006Q37227435-FB6995DD-511A-4F95-9BCE-EFC4B859F9B4Q37359616-114F84D9-5608-494E-B433-304C0638B92BQ39317074-1D2C6319-5929-4761-923E-744D825C561EQ40748761-83EBC8A6-F8D9-4880-9EB6-B32C8E1DE88FQ41196383-2B0DC101-7639-407D-8E63-301E2DC5A6ECQ43076173-038BDFE2-156B-42F7-B841-AF53782DAF19Q43118805-36C0EC45-C6A1-4BD7-8748-8B2457DD1208Q43187572-55A6C680-AC35-4C7D-9E35-1825B4978188Q43225708-F24740F7-D62A-4B1D-9A71-E97D4E141628Q43290609-6F217E13-4C1C-4391-9BF1-94BFF9B8E8C1Q44001351-A2E6EE91-3BD7-4959-898C-3869D313D51BQ44010985-F158C01C-AB5A-449B-9111-368D835CEDB7
P2860
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Characteristics of 9194 patien ...... int Reduction in Hypertension.
@en
Characteristics of 9194 patien ...... int Reduction in Hypertension.
@nl
type
label
Characteristics of 9194 patien ...... int Reduction in Hypertension.
@en
Characteristics of 9194 patien ...... int Reduction in Hypertension.
@nl
prefLabel
Characteristics of 9194 patien ...... int Reduction in Hypertension.
@en
Characteristics of 9194 patien ...... int Reduction in Hypertension.
@nl
P2093
P356
P1433
P1476
Characteristics of 9194 patien ...... int Reduction in Hypertension.
@en
P2093
F Fyhrquist
K Kristianson
L H Lindholm
M S Nieminen
O Lederballe-Pedersen
P304
P356
10.1161/01.HYP.32.6.989
P407
P577
1998-12-01T00:00:00Z